JP2025515165A - 改変されたXa因子ポリペプチドおよび使用方法 - Google Patents
改変されたXa因子ポリペプチドおよび使用方法 Download PDFInfo
- Publication number
- JP2025515165A JP2025515165A JP2024565175A JP2024565175A JP2025515165A JP 2025515165 A JP2025515165 A JP 2025515165A JP 2024565175 A JP2024565175 A JP 2024565175A JP 2024565175 A JP2024565175 A JP 2024565175A JP 2025515165 A JP2025515165 A JP 2025515165A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- factor
- seq
- nucleic acid
- apixaban
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339230P | 2022-05-06 | 2022-05-06 | |
| US63/339,230 | 2022-05-06 | ||
| PCT/US2023/066676 WO2023215879A1 (en) | 2022-05-06 | 2023-05-05 | Modified factor xa polypeptides and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515165A true JP2025515165A (ja) | 2025-05-13 |
| JP2025515165A5 JP2025515165A5 (https=) | 2026-04-28 |
Family
ID=87474126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565175A Pending JP2025515165A (ja) | 2022-05-06 | 2023-05-05 | 改変されたXa因子ポリペプチドおよび使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250302927A1 (https=) |
| EP (1) | EP4519431A1 (https=) |
| JP (1) | JP2025515165A (https=) |
| WO (1) | WO2023215879A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246094A1 (en) * | 2018-06-19 | 2019-12-26 | Portola Pharmaceuticals, Inc. | Antidotes to factor xa inhibitors |
-
2023
- 2023-05-05 EP EP23745709.8A patent/EP4519431A1/en active Pending
- 2023-05-05 WO PCT/US2023/066676 patent/WO2023215879A1/en not_active Ceased
- 2023-05-05 US US18/863,242 patent/US20250302927A1/en active Pending
- 2023-05-05 JP JP2024565175A patent/JP2025515165A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519431A1 (en) | 2025-03-12 |
| US20250302927A1 (en) | 2025-10-02 |
| WO2023215879A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2737094C (en) | Factor ix polypeptide mutant, its uses and a method for its production | |
| JP6000353B2 (ja) | プラスミノーゲンおよびプラスミンの変異体 | |
| CA2850603C (en) | Compositions and methods for modulating hemostasis | |
| KR101672108B1 (ko) | 패혈증의 치료 및/또는 개선을 위한 의약 | |
| CN112126636B (zh) | 一种高活性凝血因子XI突变体Ala570Thr | |
| JPWO1992000325A1 (ja) | 抗血液凝固活性を有するポリペプチド | |
| MX2008006313A (es) | Metodos y composiciones para modular la hemostasia. | |
| CN109260462B (zh) | 一种凝血酶原突变体蛋白及其编码核酸的应用 | |
| US10676731B2 (en) | Compositions and methods for modulating factor IX function | |
| EP2869834B1 (en) | Plasminogen activator mutants as anti-fibrinolytic agents | |
| JP2025515165A (ja) | 改変されたXa因子ポリペプチドおよび使用方法 | |
| CN108517009A (zh) | Sj13多肽及其在制备抗血栓药物中的应用 | |
| JP6629744B2 (ja) | 第Xa因子の半減期を延ばす組成物および方法 | |
| WO2016057306A1 (en) | Rho associated kinase (rock) inhibitors and their use in treating disease | |
| JP6298582B2 (ja) | トロンビン生成を調節する組成物および方法 | |
| JP2023505208A (ja) | 第viii因子の機能を調節するための組成物および方法 | |
| EP3096779A1 (en) | Compositions and methods for treating intracerebral hemorrhage | |
| WO2010078469A2 (en) | Sand fly salivary proteins as novel factor xa inhibitors and methods of use | |
| HK40088231A (en) | Factor ix polypeptide mutant, its uses and a method for its production | |
| HK40026244A (en) | Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of recombinant protein | |
| HK1130209B (en) | Therapeutic and/or ameliorating agent for disseminated intravascular coagulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260420 |